Journal article
Multiple Sclerosis, Cannabis Use, and Clinical Disability: A Preliminary [18F]-Fluorodeoxyglucose Positron Emission Tomography Study
Cannabis and cannabinoid research, Vol.3(1), pp.213-218
10/01/2018
DOI: 10.1089/can.2018.0019
PMCID: PMC6186162
PMID: 30324138
Abstract
Introduction:
Long-term consequences of medicinal cannabis use in people with multiple sclerosis (PwMS) are unknown. This study investigated whether PwMS using cannabis had lower resting brain glucose uptake (GU) and worse clinical test results compared with nonusers.
Methods:
Sixteen PwMS, eight users, underwent clinical testing followed by [
18
F]-Fluorodeoxyglucose positron emission tomography/computed tomography imaging.
Results:
Users had lower cognitive function test scores, but performed similarly on the other clinical evaluations. Accounting for disease duration, resting brain GU was similar between the groups.
Conclusions:
Lower cognitive function was not associated with resting brain GU. Cognitive dysfunction may be a contraindication or consequence of cannabis use in PwMS.
Details
- Title: Subtitle
- Multiple Sclerosis, Cannabis Use, and Clinical Disability: A Preliminary [18F]-Fluorodeoxyglucose Positron Emission Tomography Study
- Creators
- John H Kindred - Ralph H. Johnson Veteran's Administration Medical CenterJustin M Honce - University of Colorado School of MedicineJennifer J Kwak - University of Colorado School of MedicineThorsten Rudroff - University of Iowa
- Resource Type
- Journal article
- Publication Details
- Cannabis and cannabinoid research, Vol.3(1), pp.213-218
- Publisher
- Mary Ann Liebert, Inc., publishers
- DOI
- 10.1089/can.2018.0019
- PMID
- 30324138
- PMCID
- PMC6186162
- ISSN
- 2378-8763
- eISSN
- 2378-8763
- Language
- English
- Date published
- 10/01/2018
- Academic Unit
- Neurology; Health and Human Physiology
- Record Identifier
- 9984002348902771
Metrics
21 Record Views